Anthem Biosciences Ltd
ANTHEMBSE 544449BiotechnologyMkt cap ₹48,128 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹418 Cr
YoY -22.6%QoQ -31.5%
Net profit · Q1 FY27
₹120 Cr
YoY -11.7%QoQ -36.8%
Net margin · Q1 FY27
28.7%
+3.5 pts vs Q1 FY26
Net profit · FY26
₹592 Cr
YoY —
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 418 | 611 | 423 | 550 | 540 | -22.6% |
| Other income | 24.89 | 51.21 | 33.53 | 48.23 | 22.81 | +9.1% |
| Total income | 443 | 662 | 457 | 598 | 563 | -21.3% |
| Profit before tax | 145 | 278 | 130 | 230 | 186 | -22.4% |
| Tax | 24.64 | 88.16 | 37.66 | 56.17 | 50.46 | -51.2% |
| Net profit | 120 | 190 | 92.82 | 173 | 136 | -11.7% |
| Net margin | 28.7% | 31.1% | 21.9% | 31.5% | 25.1% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | YoY |
|---|---|---|
| Revenue | 2,124 | — |
| Other income | 156 | — |
| Total income | 2,280 | — |
| Profit before tax | 824 | — |
| Tax | 232 | — |
| Net profit | 592 | — |
| Net margin | 27.9% |
BIC's take
We haven't covered Anthem Biosciences Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:52 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.